Reported 1 day ago
U.S. drugmaker stocks recovered after an initial decline following President Trump's executive order to cut prescription drug prices. Analysts expressed skepticism about the order's implementation and potential legal challenges, suggesting that its impact on the sector may be limited. Major companies like AbbVie, Eli Lilly, Amgen, Pfizer, and Merck saw their shares rise between 2.1% and 4.8% despite the pressure on pharma stocks leading up to the announcement.
Source: YAHOO